# Program Announcement

<table>
<thead>
<tr>
<th>ANNOUNCEMENT TITLE</th>
<th>ASTRO-AstraZeneca Radiation Oncology Research Training Fellowship</th>
</tr>
</thead>
<tbody>
<tr>
<td>AWARD YEAR</td>
<td>2024</td>
</tr>
<tr>
<td>MECHANISM</td>
<td>Fellowship (F)</td>
</tr>
<tr>
<td>PA NUMBER</td>
<td>F-2024-02-AstraZeneca</td>
</tr>
<tr>
<td>PROGRAM PARTNER</td>
<td>AstraZeneca Pharmaceuticals LP (AstraZeneca)</td>
</tr>
<tr>
<td>POSTED DATE</td>
<td>September 28, 2023</td>
</tr>
<tr>
<td>PURPOSE</td>
<td>Physician-scientists often receive world-class training in patient care, including the newest technologies and approaches to diagnose and treat disease. However, these clinicians also require additional training in clinical research, in order to stay up to date with the pace of medical progress. As such, many radiation oncology residency programs offer a research year to these young physician-scientists to ensure they have sufficient expertise to contribute to research projects or clinical trials that will advance medical practice and improve patient outcomes. Many of these training experiences occur in an academic setting and are focused mainly on retrospective clinical analyses or basic, laboratory-based science; there is a paucity of training opportunities for clinical fellows to gain knowledge in the design, application, and uptake of the results from clinical research (including pharma-sponsored research). The Fellowship Program is designed to provide physician-scientist trainees with real-world experience in the development, administration and application of clinical trials and real-world studies at the facilities of AstraZeneca and its Affiliates in Gaithersburg, Maryland.</td>
</tr>
<tr>
<td>AWARD TERM</td>
<td>1 year</td>
</tr>
<tr>
<td>NUMBER OF AWARDS</td>
<td>2</td>
</tr>
<tr>
<td>AWARD BUDGET</td>
<td>$100,000 per award is anticipated to be awarded to the selected fellow’s Institution (“Institution”). The fellowship funds must be used for salary support for the selected fellow and a fraction of the funds can be used for travel to the ASTRO Annual Meeting. Neither ASTRO nor AstraZeneca will pay indirect costs as part of this award. No funds may be used for laboratory or other supplies. If travel is required for a Fellow to begin work at the AstraZeneca site, a limited stipend will be provided by AstraZeneca separate from the grant funding through AstraZeneca’s expense reimbursement systems.</td>
</tr>
<tr>
<td>APPLICATION DUE DATE</td>
<td>January 10, 2024; 11:59 PM Eastern Standard time (GMT -5)</td>
</tr>
<tr>
<td>EARLIEST START DATE</td>
<td>July 1, 2024</td>
</tr>
</tbody>
</table>
**PROGRAM FORMAT**

The fellow is anticipated to remain an affiliate of the fellow’s home institution but receive research training at an AstraZeneca corporate site under the development by and supervision of AstraZeneca.

Before starting the fellowship, the fellow, the fellow’s home institution and ASTRO must mutually agree to the Terms and Conditions of the Fellowship award. In addition, the fellow, the fellow’s home institution, and AstraZeneca will develop a separate written Research Agreement with mutually agreed terms including intellectual property arrangements. In the Research Agreement, the fellow and AstraZeneca will document the proposed research training experiences designed to broaden the fellow’s scientific background and maximize the fellow’s acquisition of new knowledge and skills that will enhance the fellow’s potential to become a productive and independent investigator. The Research Agreement will also document the availability of AstraZeneca’s staff, support, and facilities for high-quality training.

All work will be conducted at an AstraZeneca research site and not at the fellow’s home Institution or any other academic sites.

**SCOPE OF RESEARCH**

The fellow can expect to work with AstraZeneca on multiple projects related to company assets, both with approved indications and those in development. These range from development of medical strategies, product launch plans, and investigating aspects throughout the entire patient journey (from diagnosis to treatment). Opportunities to gain exposure to the drug development process from discovery through late-stage clinical trials are available, but hands-on experience is somewhat limited. Research opportunities include application of AstraZeneca products and clinical studies as real-world evidence, post-marketing studies, and other evidence generation strategies. Opportunities within AstraZeneca programs focused on immuno-oncology and targeted therapies as treatment strategies for non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) are included.

**PROGRAM CONTACT**

- Email questions about this PA to the Department of Scientific Affairs at science@astro.org.
- Technical questions about the ProposalCentral submission system should be directed to their customer support at 1-800-875-2562 (Tollfree U.S. and Canada) or by email pcsupport@altum.com. Support is available during normal business hours: 8:30 am - 5:00 pm Eastern Time (Monday through Friday).
ASTRO Membership
The individual applicant must be a current and active ASTRO member, or have submitted an application for ASTRO membership, as of the due date of the fellowship application. If selected, the fellow will be required to maintain their ASTRO membership throughout the duration of the fellowship.

Degree Requirements
The individual applicant must hold a medical degree such as M.D./Ph.D., M.D., D.O., or other equivalent degree(s) as of the due date of the fellowship application. Strong clinical experience, including clinical research experience are highly desired.

Residency Program, Other Trainee Status, and Institutional Affiliation
An eligible applicant must be enrolled in an accredited radiation oncology residency program at an academic, medical or research institution within the United States, and have accumulated at least two years of clinical training by the start of the Fellowship term. Alternatively, the individual applicant can also be someone who previously graduated from a radiation oncology residency program, yet currently maintains a trainee status (such as a postdoctoral training appointment or an advanced degree program) under an U.S. domestic Institution during this ASTRO-AstraZeneca Radiation Oncology Research Training Fellowship. The individual applicant must be able to secure sufficient time (1 year) for the fellowship at AstraZeneca starting July 1, 2024. Faculty members or equivalent status are not eligible to apply.

The Institution must be a U.S. domestic organization, defined as “a public (including a State or other governmental agency) or private non-profit or for-profit organization that is located in the U.S. or its territories, and, is subject to U.S. laws, and assumes legal and financial accountability for awarded funds and for the performance of the fellowship-supported activities.” Once designated in mutual agreement with the applicant, the Institution is legally responsible for providing financial and progress reports as required by ASTRO, and financially responsible for the use and disposition of any funds awarded based on the application.

COMMITMENT FROM THE FELLOW

• The fellow must designate a mentor at their training program’s Institution who will provide guidance and support for the research training opportunity. The fellow will also be assigned an AstraZeneca mentor who will oversee the fellowship activities.
• Because of the focus on progression to independence as a researcher, the fellow should propose a career development plan that is consistent with their previous training and suited to their career development needs.
• Since the goal is to provide the fellow with a research training opportunity in industry, the fellow is not allowed to maintain additional research related grant support while serving in the fellowship program.
• The fellow is required to contact ASTRO immediately if any problems are encountered that would prevent them from successfully completing the fellowship.
• The fellow is to attend at least one ASTRO Annual Meeting.

COMMITMENT FROM THE FELLOW’S INSTITUTION
• The fellow’s home Institution must be willing to allow the fellow to train at the facilities of AstraZeneca and its Affiliates in Gaithersburg, Maryland, during the trainee’s research time.

• The fellow’s home Institution must sign an agreement with ASTRO and another independent agreement with AstraZeneca to allow the fellow to train at AstraZeneca. The agreement with AstraZeneca will include terms on the handling of intellectual property developed while the fellow is conducting research training at AstraZeneca. The ASTRO Terms & Conditions for this Award are attached and should be shared with organizational officials before applications are submitted.

• The fellow and the fellow’s home Institution must make a good faith effort to complete all agreements in a timely manner (prior to the July 1, 2024 start date).

• The host department will act as the fiscal intermediary. The Institution will pay the salary to the fellow and be responsible for satisfying tax withholding, deposit and/or reporting requirements applicable to the payment of the award. The fellow will be responsible for individual income taxes.

• ASTRO and AstraZeneca do NOT pay Institutional facility and administrative costs. Funds provided under this fellowship program will be used to pay salary and benefits for the recipient (at the level of $100,000). Up to $3000 may be used to reimburse travel and registration costs to attend the ASTRO Annual Meeting. Depending on the AstraZeneca research location, a housing relocation allowance may be added.

• The fellow’s home Institution will be required to provide sufficient additional funds to supplement the fellow’s salary or other fees.

• The fellow’s home Institution will maintain insurance for medical professional liability and comprehensive general liability during the fellowship period.

• Any change in the fellow’s Institution, department chair, mentor, or the fellow’s position that might affect the fellow’s ability to successfully complete the fellowship should be communicated as soon as possible to ASTRO Department of Scientific Affairs so that appropriate action can be taken.

APPLICATION GUIDELINES

Applications must be submitted online at ProposalCentral:
https://proposalcentral.com/ProposalGI.asp?SectionID=7493&ProposalID=-1

Formatting

All materials MUST be prepared in English, single-spaced with normal spacing between letters and words, using a font style such as Arial or Times New Roman and font size between 10 and 12. A minimum of one-half inch margins must be used on all page borders.

Each section must be loaded into ProposalCentral. Applicants can stop at any point and save the application to be completed by the deadline.

Submission Content

All applications must contain the following:
1. **Personal statement** (Recommended length 2 pages): A detailed personal statement that outlines the following:
   - Prior research and clinical experience;
   - Dedication to work in radiation oncology;
   - Value provided to the research field based on the Scope of Research outlined in this announcement;
   - Intention for pursuing this Fellowship; and
   - Future professional goals and plans.

2. **Biosketch**: The applicant must submit an NIH style biosketch including a list of relevant publications and currently funded research projects (5-page limit).

3. **Academic mentoring plan**: Such a mentoring plan for the applicant during the fellowship period must be developed jointly by the applicant and the applicant's academic mentor(s). (1,500-character limit (with spaces))

4. **Letters of recommendation (2)**: Upload two letters of recommendation outlining previous work, dedication to a research career, and characteristics that make this opportunity in industry a particularly good option for the applicant. One letter must be from the Institutional mentor.

5. **Institutional letter of recommendation (1)**: Upload a letter of support from the resident’s department chair. This letter must document that the department chair supports this Fellowship program and acknowledge that the resident, if selected, will conduct research at an AstraZeneca site.

Applications lacking the required content or in the incorrect format will be considered ineligible for review. Materials submitted after the deadline will not be accepted.

No additional data or documentation such as accepted manuscripts or received awards will be accepted.

Applications to this fellowship program might also be considered for other active ASTRO-Industry Radiation Oncology Research Training Fellowship opportunities for the 2023-2024 funding cycle.

**APPLICATION REVIEW**

All fellowship applications are subject to peer review by the fellowship Scientific Review Committee (SRC). Reviewers are members of the ASTRO Scientific Review Panel or other ASTRO-approved ad hoc expert(s) as necessary, and members recommended by AstraZeneca. All members serving on the SRC will be required to report any conflict of interest, before reviewing applications and to execute an undertaking related thereto. The reviewers will convene to recommend an awardee following the peer review. Final decisions will be subject to the approval of the ASTRO Board of Directors.

Selected candidates will be those who demonstrate a strong clinical background, a desire to work in an academic or industry setting, and a well-crafted plan for a future research career.

SRC will consider the following factors of an applicant during the application review process:
- General qualifications, clinical and scientific background;
Commitment in pursuing a research career in radiation oncology either within an academic or industry setting;
• Motivation and enthusiasm about the field of research with immunooncology, targeted agents, and radiation combinations in patients with NSCLC and SCLC;
• Academic publications;
• Availability and commitment to conduct the research training at an AstraZeneca site;
• A statement that outlines how this opportunity can further the applicant’s research career; and
• A mentoring plan developed by the applicant and the applicant’s academic mentor(s).

OTHER INFORMATION
• Applicants should be aware that receipt of this fellowship may be reported by AstraZeneca to government entities or otherwise to third parties, as required by law or pursuant to AstraZeneca policy.
• Non-disclosure and intellectual property arrangements regarding the research training projects and other activities of the fellow during the fellowship will be addressed and mutually agreed upon in the Research Training Agreement among AstraZeneca, the prospective Fellow, and the fellow’s home Institution, prior to conferral of Fellowship.
• If travel is required for a Fellow to begin work at the AstraZeneca site, a limited stipend that complies with applicable laws may be provided by AstraZeneca separate from the grant funding through AstraZeneca’s expense reimbursement systems. This stipend is intended to allow the Fellow to travel to the AstraZeneca site prior to the start of the term to secure housing accommodations needed for the term. In addition, this stipend also could cover necessary costs for the Fellow to travel to the AstraZeneca site at the beginning of the term spent on site, and to return home at the end of that term. The total amount of the stipend will be determined on a case-by-case basis, and will be dependent upon the distance travelled by the Fellow, but will be no more than $7,500. Housing costs for the Fellow during the one-year term at the AstraZeneca facility shall be the responsibility of the Fellow. AstraZeneca and the Fellow shall arrange directly with each other for the appropriate amount of such stipend and for payment through AstraZeneca’s expense reimbursement system.
• The Terms and Conditions for this award are attached to this Program Announcement as a reference for organizational signing official.
ASTRO-PLACEMENT ORGANIZATION Radiation Oncology Research Training Fellowship

TERMS AND CONDITIONS BETWEEN ASTRO AND INSTITUTION

THIS FELLOWSHIP AGREEMENT ("Agreement") is by and between the American Society for Radiation Oncology ("ASTRO") and INSTITUTION ("Institution"), each of which may be referred to in the singular as "Party" or in the plural as "Parties." The Agreement is made effective on MONTH XX, [YEAR].

WHEREAS ASTRO and PLACEMENT ORGANIZATION created a program called the ASTRO-PLACEMENT ORGANIZATION Radiation Oncology Research Training Fellowship to support research and mentorship in the radiation oncology field (the "Fellowship Program"); and

WHEREAS under this Fellowship Program, a research fellow is selected to conduct research training activities on site at PLACEMENT location using funds provided by PLACEMENT ORGANIZATION, and ASTRO administers the promotion, selection and funding of the Fellowship Program, in coordination with PLACEMENT ORGANIZATION and applicable sponsoring academic institutions; and

WHEREAS individual applicant listed below has been selected and desires to participate as a fellow in the Fellowship Program as set forth in the mutual covenants contained in this Agreement; and

WHEREAS applicant’s current academic institution listed below desires to sponsor the selected applicant’s participation in the Fellowship Program as set forth in the mutual covenants contained in this Agreement;

NOW THEREFORE, in consideration of the mutual covenants contained in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties, intending to be legally bound, agree as follows:

I. Definitions. The following definitions shall apply in this Agreement:

A. "PLACEMENT ORGANIZATION" is the company that has provided the funding for this opportunity for the Fellow and is responsible for designing and administering the specific research training experience for the Fellow that will take place at a facility of PLACEMENT ORGANIZATION and will relate to radiation oncology research training.

B. "Confidential Information" means, for each person or entity ("Entity"), any information disclosed by that Entity to a Party for use in the Fellowship Program, the Fellowship activities, the terms of this Agreement and any other information whether of a technical, business or other nature, including but not limited to, Progress Reports, medical records, or Study Data, as well as, inventions or discoveries, products, formulae, processes, techniques, promotional material, developments, proprietary rights or business affairs of that Entity. However, the term Confidential Information excludes information that: (i) is generally known by the public other than through breach of this Agreement or an obligation of confidence owed to the Disclosing Entity; (ii) the Recipient Party can prove was already known to it at the time of disclosure by the Disclosing Entity (unless that knowledge arose from disclosure of information in breach of an obligation of confidence); (iii) the Recipient Party acquires from a source other than the Disclosing Entity or any employees, student, agents, officers, directors, auditors, advisers, partners, consultants, of the Disclosing Entity where that source is entitled to disclose it; or (iv) is independently developed by Recipient Party or any student, employee, agent, officer, director, auditor,
adviser, partner, consultant, licensee, sublicensee, joint venture or subcontractor of the Recipient Party who had no access to the Confidential Information.

C. “Deliverables” are the progress reports, financial reports, and other materials to be produced or submitted with respect to the Fellowship Activities that ASTRO, the Institution, and the Fellow have agreed upon in connection with receipt of funding for the Fellowship.

D. “Fellow” means a candidate selected to receive a Fellowship position and the accompanying funding under the Fellowship Program as described herein.

E. “Fellowship Funds” are the amount of funds that ASTRO is awarding to the Institution to cover the cost of the Fellow’s participation in the Fellowship as further described in Section II.

F. “Fellowship Term” shall mean the period of performance for this Agreement, which begins on the Effective Date and ends on the first anniversary of the Effective Date, unless ASTRO, the Fellow, the Institution and PLACEMENT ORGANIZATION agree to extend the term of the Fellowship for an additional year.

G. “Fellowship Activities” are the radiation oncology research training activities to be carried out by the Fellow under the direction of PLACEMENT ORGANIZATION mentor.

H. “Study Data” are confidential records and reports, other than medical records, collected or created pursuant to or prepared in connection with the Fellowship Activities including, without limitation, reports (e.g., case report forms, any data summaries, any interim, annual, or final report) and all information regarding inventories and disposition of all drugs and devices used in or resulting from the Fellowship Activities to the extent housed or maintained at the Institution, PLACEMENT ORGANIZATION, and/or by the Fellow.

II. Award of Fellowship.

A. ASTRO shall provide the Institution with Fellowship Funds in the amount [specified in the Program Announcement] for the Fellow for one year. These Fellowship Funds will be paid to Institution as set forth in Section IV to offset the cost of Fellow’s salary and benefits for the year. The payment of Fellowship Funds is made contingent on the execution of this Agreement, mutually agreeable Fellowship Research Agreement(s) (“Research Agreement”) between the Fellow, Institution and PLACEMENT ORGANIZATION, as addressed in Section X, as well as Fellow’s agreement to forego any other funding that would require relinquishment of the Fellowship.

Fellow and Institution expressly consent to allow ASTRO to provide any and all information provided or obtained in the Fellowship selection and award process about the Fellow and Institution to PLACEMENT ORGANIZATION or others involved in the Fellowship Program for purposes of carrying out their responsibilities under the Fellowship Program.

B. Fellow’s attendance at the ASTRO Annual Meeting and any Fellowship recognition event is strongly encouraged. Up to $3,000 of the Fellowship Funds shall be allocated to offset the Fellow’s registration and attendance costs at the ASTRO Annual Meeting.

III. Term.
A. The Term of this Fellowship Agreement is one year beginning on the Effective Date unless ASTRO, the Fellow, the Institution and PLACEMENT ORGANIZATION agree to extend the term of the Fellowship for additional time.

B. If the Fellow is unable to commence the Fellowship by the Effective Date, ASTRO must be immediately notified. ASTRO retains the right to terminate the Fellowship if the Fellowship is not, or will not be, commenced within 30 days of the Effective Date, unless prior approval from ASTRO is obtained.

C. Notwithstanding anything in this Agreement to the contrary, the term of this Agreement, as well as any continuation of the term of this Agreement for each successive year of the Fellowship Term (if any), is contingent on receipt by ASTRO of funding for this Fellowship for such term from PLACEMENT ORGANIZATION. If ASTRO fails to receive such funding from PLACEMENT ORGANIZATION, ASTRO may terminate this Agreement by written notice to Fellow and the Institution given as soon as reasonably possible after learning of the lack of funding.

IV. Payments.

The Fellowship Funds shall be paid in one installment to the Institution at the beginning of the Fellowship Effective Date.

V. Use of Fellowship Funds.

A. The Institution shall be responsible for administering use of the Fellowship Funds. All disbursements must be in strict accordance with this Agreement. The Institution shall be liable for reimbursement to ASTRO of any Fellowship Funds associated with any inappropriate or unauthorized expenditures of Fellowship Funds or fraudulent or improper conduct involving the use of Fellowship Funds. The Institution shall ensure that costs charged to the Fellowship Funds are allowable, allocable, reasonable, necessary, and consistently applied. ASTRO may disallow any cost if it determines, through audit or otherwise, that the cost does not meet the tests of allowability, allocability, reasonableness, necessity, and consistency.

B. Fellowship Funds are to be used for salary and benefit expenses of the Fellow, as well as Fellow’s registration and travel to the ASTRO Annual Meeting during the Fellowship Term. No other expenses are permitted, except as otherwise specified in this Agreement. During the year spent at the PLACEMENT ORGANIZATION facility, the Fellow must dedicate 100% effort to the Fellowship Activities.

C. Fellowship Funds may not be used for salary and benefit expenses of any individuals other than the Fellow, tuition, travel (other than to the ASTRO Annual Meeting as noted in Section II), laboratory supplies, or any other research-related expenses. For the purposes of this Fellowship, any general office supplies or individual institutional administrative charges (e.g., telephone, other electronic communication, utilities, IT network, etc.) are considered to be indirect and are not allowable expenses. For avoidance of doubt, no Fellowship Funds may be directed towards salary or benefits of any individuals from a U.S. government entity or for-profit industry, nor for any research expenses related to the Fellowship Activities that are incurred by these individuals. Fellowship Funds may not become part of the Institution’s or any organization’s endowment fund, capital campaign, construction, or renovation costs.
D. No Fellowship Funds provided may be used for any political campaign, or to support attempts to influence legislation by any governmental body, other than making available the results of nonpartisan analysis, study, and research.

E. Funding for the Fellow from other sources in addition to the [YEAR] ASTRO-PLACEMENT ORGANIZATION Radiation Oncology Research Training Fellowship is not permitted. Institution is responsible for determining whether acceptance of this Fellowship would jeopardize support the Institution or Fellow may receive from other sources. Institution must require Fellow to document any additional funding supporting the Fellowship Activities, or other research that may significantly affect the Fellowship Activities, in the progress reports described in Section VIII. Fellow and Institution are required to notify ASTRO in writing via email about any additional funding that the Fellow or Institution receives for the Fellow, no later than 3 business days after the confirmed receipt of such additional funding. Institution and Fellow are required to respond to requests from ASTRO for additional information about other funding, such as budgets and project aims, for an evaluation of potential overlap. The Fellow may be required to relinquish the Fellowship and Fellowship Funds, if additional funding to support the Fellow is secured outside the [YEAR] ASTRO-PLACEMENT ORGANIZATION Radiation Oncology Research Training Fellowship.

F. The Institution shall return to ASTRO any unexpended Fellowship Funds upon the expiration or earlier termination of this Agreement.

VI. Term at PLACEMENT ORGANIZATION.

A. Subject to the Research Agreement with PLACEMENT ORGANIZATION, if travel is required for Fellow to begin work at the PLACEMENT ORGANIZATION site, a limited stipend may be provided directly by PLACEMENT ORGANIZATION to the Fellow through PLACEMENT ORGANIZATION’s expense reimbursement system. This stipend is dependent on the rules of PLACEMENT ORGANIZATION and the terms of the Research Agreement between Fellow and PLACEMENT ORGANIZATION, and may not be available for all Fellowships. These expenses may only be paid for with a stipend and are not eligible expenses to be paid for with Fellowship Funds. No Fellowship Funds will be used to pay for travel, other than to the ASTRO Annual Meeting as described in Section II, unless the specific expense is explicitly approved in writing in advance by both ASTRO and PLACEMENT ORGANIZATION. Housing costs for the Fellow during the term at the PLACEMENT ORGANIZATION facility shall be the responsibility of the Fellow, unless otherwise indicated in the Program Announcement or Research Agreement.

B. Fellow will spend the Fellowship Term on the premises of PLACEMENT ORGANIZATION to perform the Fellowship Activities under the supervision of PLACEMENT ORGANIZATION. PLACEMENT ORGANIZATION has agreed to design the program to provide a meaningful research training experience for the Fellow, in compliance with applicable laws and the responsible ethical conduct of research. ASTRO makes no representation regarding the work, work conditions, or location provided under this Fellowship and disclaims all liability for them. ASTRO expressly disclaims any liability for any visa or passport issues that may arise as part of this Fellowship. Fellow and Institution shall notify ASTRO as soon as possible after becoming aware of any issues that may prevent Fellow’s travel to the PLACEMENT ORGANIZATION location. Fellow and Institution bear full responsibility for determining whether or not to enter into the Fellowship and any agreements related to the Fellowship, as well as what provisions to include regarding Fellow’s work situation, living situation, research experience, and
all other aspects of Fellow’s work at PLACEMENT ORGANIZATION. If at any time over the course of the Fellowship, concerns arise regarding the work, working conditions or any other aspect of the Fellowship, the Fellow and Institution each agree that they shall immediately notify ASTRO.

C. When on PLACEMENT ORGANIZATION premises, Fellow shall conduct only the agreed Fellowship Activities and no other work. In carrying out the Fellowship Activities at the PLACEMENT ORGANIZATION site, Fellow will be subject to all applicable PLACEMENT ORGANIZATION policies and procedures, including but not limited to: those contained within policies covering health and safety, smoking, fire, the use of computers, and any legal or regulatory rules, policies or procedures adopted by PLACEMENT ORGANIZATION. PLACEMENT ORGANIZATION is responsible for ensuring that Fellow receives all relevant notice of policies and procedures, requirements and training to enable Fellow to undertake Fellow’s duties during the performance of the Fellowship Activities.

VII. Change in the Status of Fellow, Use of Funds, or Performance.

A. ASTRO reserves the right to terminate the Fellowship if: (i) the Fellow’s position, Institution, or other support changes substantially from what was described in the Application, (ii) if funding is terminated by PLACEMENT ORGANIZATION; or (iii) if substantial issues regarding the Fellowship experience or administration arise and cannot be resolved in a timely manner, including but not limited to Fellow’s attendance or performance at a level of significance that jeopardizes the funding from PLACEMENT ORGANIZATION.

B. If the Fellow is appointed to a new position at the Institution during the Fellowship Term, Institution is required to notify ASTRO in writing within 15 days of notice to the Fellow of such appointment so that ASTRO may determine if the continuation of the Fellowship is appropriate.

C. If the Fellow notifies the Institution of an intent to transfer to a new institution during the Fellowship Term, the Institution is required to notify ASTRO in writing within 15 days of receipt of such notice from Fellow. The Fellowship will be terminated unless a written request is made to ASTRO by Fellow to transfer the Fellowship and mutually agreeable arrangements can be made among all the parties, including Fellow, Fellow’s old institution, Fellow’s new Institution and PLACEMENT ORGANIZATION.

D. The Institution and the Fellow shall notify ASTRO of any absence from professional duties by the Fellow during the Fellowship Term that extends 30 or more days and the reason for such absence. Absenteeism may jeopardize funding.

VIII. Reporting Requirements.

A. Funding is contingent upon compliance by the Fellow and Institution with the reporting requirements set forth herein and approval of the reports by ASTRO as described in this Section. Progress, and financial reports are due to ASTRO according to the due dates listed below. Progress, and financial reports must be submitted utilizing the templates provided by ASTRO. ASTRO will inform the Fellow and Institution of approval or deficiencies in reports.

B. Required Reports and Presentations. The Institution is responsible for the Fellow’s compliance with the following reporting requirements:

1. Interim Reports. The Fellow shall submit an interim progress report including expenditures corresponding to the first six months of the Fellowship Term summarizing the program to date and
outlining any issues that would preclude the Fellow from successfully completing the Fellowship. Evaluation of the program including suggestions to improve solicitation and management of the program are strongly encouraged. The interim report should also contain a review of the Fellow’s efforts at PLACEMENT ORGANIZATION by the PLACEMENT ORGANIZATION mentor to ensure productivity on the Fellowship Activities and a meaningful research training experience for the Fellow.

2. Final Reports. Final progress and financial reports shall be submitted to ASTRO no later than 60 days after the ending date of the Fellowship Term. Fellows may not receive other ASTRO Grants or ASTRO Fellowships until the final reports are received and considered acceptable by ASTRO. The final progress report should be substantive and comprehensive.

C. The submission dates for reports are as follows.

1. Interim Reports: No later than 30 days, 6 months after the Fellowship Effective Date.

2. Final Progress Report: No later than 60 days after the Fellowship termination.

IX. Publicity and Acknowledgment of Support.

A. By accepting this Fellowship, the Institution and Fellow give ASTRO and PLACEMENT ORGANIZATION permission to include Fellowship information (including but not limited to Fellow’s name, photographs, degrees, institution, grant amount and general topic of research) in publicly accessible databases and to publish such information in other media as set forth below. ASTRO will provide copies of interim and final progress reports to PLACEMENT ORGANIZATION or its designees, including copies submitted by the Fellow of any publications and/or press releases and/or other publicity materials generated by the Institution. ASTRO and/or PLACEMENT ORGANIZATION or designees may use publicly non-confidential and/or previously published information from the reports for public dissemination, such as within their newsletters, on websites, or in other similar public resources; provided, however, that, if without clear consent from Institution or PLACEMENT ORGANIZATION, ASTRO shall not knowingly make any disclosure of confidential information as previously designated by either Institution or PLACEMENT ORGANIZATION. To facilitate such public dissemination, the Fellow and Institution shall fully cooperate with ASTRO in responding to ASTRO’s reasonable requests for information with respect to the Fellowship. ASTRO recognizes that information contained within interim, and final reports clearly marked as confidential should be treated as such and will obtain prior approval from the appropriate parties before disclosing Confidential Information publicly.

B. After the Fellowship Term has expired, the Fellow agrees to continue to respond to ASTRO and PLACEMENT ORGANIZATION’s reasonable requests for information on their career progress and may be requested to provide their current Curriculum Vitae, update their contact information, or provide other relevant information. The Fellow understands that this obligation survives the Fellowship Term and that they have an ongoing reasonable obligation to provide this information.

C. Any publications or patents resulting from research funded in whole or in part by the Fellowship must be cited as follows: “This research is supported by the [YEAR] ASTRO-PLACEMENT ORGANIZATION Radiation Oncology Research Training Fellowship.” In addition, whether during the term of the Fellowship or afterwards, the Fellow and the Institution shall include this citation on any publicity or communications (external or internal) resulting from the Fellowship, including but not limited to press
releases, media reports, interviews, conference talks, and poster presentations of Study Data. Copies of all such publications must be forwarded to ASTRO.

D. Any reference to the 2023 ASTRO-PLACEMENT ORGANIZATION Radiation Oncology Research Training Fellowship shall include the Fellowship name in its entirety.

E. The Fellow, Institution, ASTRO, and PLACEMENT ORGANIZATION may state factually on any of their websites and other materials the information authorized or approved per this Agreement. Furthermore, ASTRO and PLACEMENT ORGANIZATION may issue a press release and make public statements regarding the award of the Fellowship, the identity of the recipient Fellow and Institution and the general nature of the Fellowship Program, purpose and research as developed by ASTRO for such publication. In the event that a Party wishes to make any other press or other announcement or release relating to this Agreement, the Fellowship Program, or the Fellowship Activities occurring under this Agreement, that Party will discuss with, and obtain advance written agreement from PLACEMENT ORGANIZATION and ASTRO and, if referenced, the Fellow and such Fellow’s Institution, regarding the content, form and manner of the announcement or release. If, and to the extent that the announcement or release is required to be made by the Party by law or by a stock exchange regulation, the announcement or release will be cleared with the other Party, the Fellow and the Institution to the greatest extent possible prior to its release and be based, to the greatest extent possible on previously approved language.

F. No external announcement, press release, or other public statement shall be made by the Fellow, Institution, or any of its affiliated members, agents, or subcontractors to publicize their involvement with the Fellowship Activities, regardless of the medium used, without prior written approval of the ASTRO and PLACEMENT ORGANIZATION, unless required by law or regulation, or to respond to an urgent situation in which it is unreasonable to secure prior approval. ASTRO will use its best efforts to review the language as promptly as possible and its approval will not be unreasonably withheld or delayed. ASTRO will coordinate with PLACEMENT ORGANIZATION regarding its review and will use its best efforts to obtain PLACEMENT ORGANIZATION’s approval of the language. ASTRO will provide Fellow and Institution with reasonable advance notice and an opportunity to comment prior to issuing any public statement regarding the Fellowship Program.

G. Except as provided in this Agreement regarding acknowledgment in publications, prior approval must be obtained from ASTRO for any use of the logos, trademarks, or service marks of ASTRO.

H. ASTRO requires that the Institution list the annual support provided to the Institution by this Fellowship whenever Institution lists grantor-supported research during the term of this Agreement.

X. Fellowship Research Agreement.

The Fellowship will be contingent upon the execution of a Research Agreement that contains mutually acceptable provisions regarding the type of work, research experience, work setting and conditions, applicable standards and requirements for the Fellow as well as the confidentiality and ownership of and rights to any intellectual property results and publication of such results, as are determined between PLACEMENT ORGANIZATION, the Institution, the Fellow, and any third-party collaborators. The Parties will use good faith efforts to advance negotiation and execution of the Research Agreement to enable timely confirmation of the Fellowship and commencement of the Fellowship by the planned Effective Date. ASTRO’s involvement with the Fellowship is limited to administering the funding and
review of progress reports, and ASTRO plays no role in the development, implementation or enforcement of the Research Agreement between Fellow, Institution and PLACEMENT ORGANIZATION. If, however, the Fellow, Institution or PLACEMENT ORGANIZATION believes the Research Agreement is being breached, or has failed to properly address a substantial issue affecting the Fellowship then each agrees to promptly notify ASTRO in writing advising of the issue and working with them to reach a resolution.

XI. Confidentiality.

A. No Confidential Information disclosed by one Entity (“Disclosing Entity”) to a Party (“Recipient Party”) under this Agreement or Fellowship Program, or a Research Agreement hereunder, may be used or disclosed by the Recipient Party or any third party except in the performance of this Agreement, in accord with the terms of this Agreement or per written authorization from the Disclosing Entity.

Upon termination of this Agreement for any reason, Recipient Parties agree to cease using and to return to Disclosing Entity or destroy all whole and partial copies and derivatives of the Confidential Information, whether in Recipient Party's possession or direct or indirect control. The requirements to return or destroy do not apply to copies of electronically exchanged Confidential Information made as a matter of routine information technology backup.

In addition to the exclusions specified in I(C), the confidentiality obligations of this Section shall not apply to information that is required to be disclosed to comply with applicable laws or regulations, or with a court or administrative order, provided however that Recipient Party provides Disclosing Entity with sufficient prior written notice of that intended disclosure, when possible, such that Disclosing Entity may seek reasonable legal remedies to prevent or minimize disclosure and/or to obtain confidential treatment for that Confidential Information. Recipient Party shall cooperate with Disclosing Entity in seeking these remedies and/or confidential treatment.

B. The provisions of this Section will survive the expiry or earlier termination (for whatever reason) of this Agreement.

XII. Acknowledgement and Authorization of Reporting.

The Fellow and Institution acknowledge and provide authorization for ASTRO and PLACEMENT ORGANIZATION to report information including their names and payment amounts as deemed appropriate to comply with applicable laws.

XIII. Waiver and Indemnification.

Disclaimer: ASTRO IS A PASSIVE GRANTOR AND HEREBY DISCLAIMS ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, CONCERNING THE FELLOWSHIP. UNDER NO CIRCUMSTANCE SHALL ASTRO BE LIABLE TO ANY RECIPIENT, OR ANY OTHER PERSON OR ENTITY, FOR ANY DAMAGES ARISING FROM OR IN RELATION TO THIS FELLOWSHIP (WHETHER IN CONTRACT, TORT, NEGLIGENCE, STRICT LIABILITY, BY STATUTE, REGULATION OR OTHERWISE).

The Institution and Fellow enter into this Agreement, any other Agreements related to the Fellowship with PLACEMENT ORGANIZATION, as well as any and all activities related to the Fellowship, including, but not limited to the activities at the location(s) or related to the work undertaken during the Fellowship, with the full knowledge that ASTRO is not involved in designing or overseeing those activities. Institution and Fellow have sole responsibility for their decision to accept the Fellowship and
enter into the agreements related to it. Except with regard to claims related to ASTRO’s breach of this Agreement, Institution hereby agrees to waive any claims against ASTRO, its directors, staff, or volunteers related to the Fellowship Program. The Institution agrees to indemnify ASTRO, its directors, officers, employees, and agents for all loss or damage suffered by these indemnities arising from third party claims related to (1) non-research activities performed by the Fellow to fulfill medical education requirements, including any clinical rotation practice activities and/or (2) the negligent acts or omissions of Institution or Fellow with respect to the obligations undertaken pursuant to this Fellowship Program, but only to the extent such claims do not result from the negligence, recklessness or willful misconduct of ASTRO or any of its officers, directors, employees, agents or contractors.

In addition, Institution agrees to be responsible for any and all claims, liabilities, losses, and expenses (including attorneys’ fees) to the extent arising from or caused by any of Institution’s or Fellow’s negligent, reckless, or intentionally wrongful act or omission, including without limitation research misconduct, undisclosed conflict of interest or professional malpractice, or fraud or other misconduct in applying for or expending Fellowship Funds or in carrying out, or reporting on, the Fellowship.

XIV. Termination.

A. Fellow may not terminate the Fellowship Agreement prior to the end date without good cause and prior written approval from ASTRO. Failure to obtain such approval may constitute a breach of this Agreement. Institution shall require Fellow to comply with this provision and provide ASTRO with prompt notice of any intent to terminate the Fellowship Agreement. If approved, the termination shall be effective on the date upon which the Fellow is notified by ASTRO of approval of Fellow’s request to terminate. Any unspent funds shall be returned to the ASTRO, and final progress reports submitted to the ASTRO within 60 days of termination.

B. Unless extended by written agreement of the Parties, or terminated as provided in this Agreement, the Fellowship Agreement is for the period of one year from the Effective Date as set forth in this Agreement and the Research Agreements between PLACEMENT ORGANIZATION, the Fellow and the Institution. ASTRO will provide the Institution with notice in writing that the Agreement has been terminated in accordance with these terms.

C. ASTRO may terminate this Agreement at any time, and cease further funding, if ASTRO determines, in its sole discretion, that the Fellow, or Institution (i) has materially breached this Agreement and such breach has not been cured within 30 days after notice is provided of said breach; (ii) has taken action inconsistent with the stated objectives of the Proposal; (iii) has committed scientific fraud including fabrication, falsification, or plagiarism in proposing, conducting, or reporting the results of the Fellowship; (iv) if the Institution ceases to be qualified as a non-profit entity that is tax-exempt under federal and state laws; or (v) if any scheduled Report is more than 90 days past due without an explanation having been provided satisfactorily to ASTRO. ASTRO retains the right to terminate the Fellowship if the Fellowship is not commenced or pursued in a timely manner as set forth in Section III. ASTRO may also terminate this Agreement if it determines in its sole discretion that PLACEMENT ORGANIZATION has materially breached the terms of the Agreement between ASTRO and PLACEMENT ORGANIZATION, or if PLACEMENT ORGANIZATION has terminated the Research Agreement, or its Agreement with ASTRO.
D. Upon notification by ASTRO of termination, a final financial report of expenditures must be submitted by the Institution with a check for the remaining balance of the Fellowship Funds, as well as final report outlining the work accomplished to date within 60 days of termination.

E. ASTRO may terminate this Agreement at any time, and cease further funding, if PLACEMENT ORGANIZATION fails to provide sufficient funds to support the Fellowship, or if PLACEMENT ORGANIZATION discontinues funding for the [YEAR] ASTRO-PLACEMENT ORGANIZATION Oncology Research Training Fellowship.

F. In the event of early termination of this Agreement by ASTRO, Institution shall be compensated on a pro-rata basis for the portion of time that Fellow has spent in the Fellowship if already begun, to the extent that such funds have been provided by PLACEMENT ORGANIZATION.

G. In the event of a termination of this Agreement pursuant to Section XIII(C), ASTRO shall be entitled to return of all unexpended Fellowship Funds. If ASTRO determines that such Fellowship Funds were improperly expended or if the benefit of the expenditure is substantially eliminated by the conduct giving rise to the termination, ASTRO also shall be entitled to receive reimbursement of expended Fellowship Funds.

H. The Institution may terminate this Agreement at any time based on a material breach of the Agreement by ASTRO, provided that such breach has not been cured by ASTRO within 30 days after notice is provided of said breach.

XV. Miscellaneous.

A. The Institution shall maintain insurance for each year of the Fellowship for medical professional liability and comprehensive general liability against claims for personal injury, including bodily injury or death, and property damage and shall provide “tail” coverage for additional years after the termination of the Fellowship sufficient to insure against any claims that may be asserted within the applicable statute of limitations. Proof of such insurance shall be provided to ASTRO upon request. The foregoing insurance requirements may also be satisfied by a program of self-insurance. The Institution shall ensure that Fellow is covered under Institution insurance. Proof of such insurance shall be provided to ASTRO upon request.

B. The Institution represents that it is, and will continue to be during the Fellowship Term of this Agreement, recognized by the Internal Revenue Service (IRS) as a non-profit entity that is tax-exempt under federal and state laws. The Institution shall notify ASTRO immediately of any change in its tax-exempt status.

C. Nothing in this Agreement shall be construed to make the parties agents of each other or partners, or to permit either party to incur any expense or bind the other to any obligation not specifically set forth herein.

D. Neither Party may assign or otherwise delegate any of its rights or obligations hereunder without the prior written consent of the other Party. Any attempted assignment in violation of this paragraph shall be null and void, without legal force or effect.

E. Any representations that are deemed to be false will constitute a breach of the Agreement.
F. Any notice(s) required or permitted to be given by this Agreement relating to the terms and conditions of this Agreement shall be in writing and shall be delivered by e-mail, postal mail, courier or shipping company, or personal delivery to the receiving party. Any notice so delivered shall be deemed to be given, delivered and received, if delivered by personal delivery, on the day of delivery and if delivered by e-mail, postal mail, or courier or shipping company, on the day following dispatch.

Notices shall be sent to:

If to Institution:

Name of Institution:
Address:
Email:

If to ASTRO:

Department of Scientific Affairs
American Society for Radiation Oncology
251 18th St South, 8th Floor,
Arlington, VA 22202

G. This Agreement and all attachments hereto constitute and contain the entire agreement and understanding between the parties, and supersede and replace all prior negotiations and all agreements, proposed or otherwise, whether written or oral, concerning the subject matter hereof. No course of dealing, usage of trade, or course of performance shall be relevant to explain, supplement or modify any express provision of this Agreement. Unless otherwise stipulated in writing, this Agreement is made with the understanding that ASTRO has no obligation to provide other or additional support to the Institution, any Fellow or any other person. This Agreement shall be governed by the laws of the Commonwealth of Virginia.

H. All payments by ASTRO to the Institution hereunder will reference the “[YEAR] ASTRO-PLACEMENT ORGANIZATION Radiation Oncology Research Training Fellowship,” and will be made in U.S. dollars. Checks will be mailed to:

Institution Mailing Address:

I. Neither party shall be liable for any failure to perform as required by this Agreement to the extent such failure to perform is due to circumstances reasonably beyond such party’s control, including, without limitation, labor disturbances or labor disputes of any kind, accident, failure of any governmental approval required for full performance, civil disorders or commotions, acts of aggression, acts of God, epidemics, energy or other conservation measures imposed by law or regulation, explosions, failure of utilities, mechanical breakdowns, material shortages, disease, or other such occurrence.

***************

ACKNOWLEDGEMENT
I, the Fellow, acknowledge that I have read and understood the terms and conditions of this Fellowship Agreement and accept to be bound personally by the Agreement and understand the provisions in the Agreement regarding the role of Fellow for the program called the ASTRO-PLACEMENT ORGANIZATION Radiation Oncology Research Training Fellowship. I authorize ASTRO’s use of my name, likeness and professional information in connection with ASTRO’s communications relating to this fellowship. I understand that ASTRO’s only role has been to assist with publication of the Fellowship, selection of Fellow, and administering the funds provided by PLACEMENT ORGANIZATION that ASTRO has not approved and is not overseeing my work projects or work environment. I WAIVE ANY CLAIMS AGAINST ASTRO, ITS DIRECTORS, OFFICERS, EMPLOYEES OR AGENTS RELATED TO THE FELLOWSHIP PROGRAM.